Conclusively, research on GLP-1R and its agonists marks a promising direction in metabolic disease therapy, extending their potential beyond glucose regulation and offering hope for more comprehensive approaches in addressing metabolic diseases
[1] Tirzepatide (Mounjaro, Zepbound) has a half-life of approximately 5 days, with elimination taking about 4-5 weeks after the last dose
(2025) 166:bqae167
This approach supports steady weight loss, ideal for individuals aiming to lose a smaller amount of weight or improve overall health
Multiple Sclerosis Considering the potential of GLP-1RAs for the treatment of NDD, multiple sclerosis, a chronic progressive autoimmune disease caused by autoantibodies that stimulate inflammation and destruction of the myelin sheath of neuronal axons, disrupting axonal conduction and function should also be mentioned
There are also motility alterations, such as diarrhea explained by the rapid colonic transit, as GLP1 activates intrinsic afferent neurons containing calcitonin gene-related peptide that favors the frequency of peristaltic contractions (158) or constipation due to mechanisms dependent on nitric oxide and AMPc/PKA that reduces colon contractility (159)